4basebio (LON:4BB) Stock Price Down 1.4% – Here’s What Happened

4basebio PLC (LON:4BB)’s share price was down 1.4% during trading on Monday . The stock traded as low as GBX 501.63 and last traded at GBX 501.63. Approximately 2,809 shares were traded during trading, an increase of 75% from the average daily volume of 1,606 shares. The stock had previously closed at GBX 508.80.

4basebio Price Performance

The business’s 50-day simple moving average is GBX 567.81 and its 200 day simple moving average is GBX 685.06. The company has a market capitalization of £84.39 million, a P/E ratio of -5.51 and a beta of 1.09. The company has a current ratio of 2.73, a quick ratio of 3.52 and a debt-to-equity ratio of 201.47.

Insider Activity at 4basebio

In other news, insider Heikki Lanckriet bought 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 10th. The shares were purchased at an average price of GBX 576 per share, with a total value of £17,280. Also, insider Amy Walker bought 2,650 shares of the company’s stock in a transaction that occurred on Friday, February 13th. The shares were purchased at an average cost of GBX 586 per share, for a total transaction of £15,529. Insiders have purchased 6,650 shares of company stock worth $3,865,900 over the last quarter. 12.07% of the stock is currently owned by company insiders.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.